Prøve GULL - Gratis
“Singapore has been a great launchpad, owing to its structured safety frameworks”
BioSpectrum Asia
|BioSpectrum Asia Sep 2025
The increasing prevalence of occupational injuries and illnesses is one of the primary factors fueling the growth of the occupational health market, valued at $5.45 billion in 2025, across the globe. With the Asia Pacific (APAC) region occupying the third-largest share in this market, after the US and Europe, we see a number of companies deploying technologies to unlock tremendous opportunities within the occupational health sector. Singapore-based startup TacnIQ AI is one such example, taking a proactive approach to address the health risks associated with workplace management, through technology. Their flagship product Backy is an artificial intelligence (AI)-powered wearable designed to prevent musculoskeletal injuries in physically demanding jobs. It delivers posture feedback in real time to workers, helping reduce back strain and injury risks. In an exclusive interview with BioSpectrum Asia, TacnIQ's Co-Founder and Chief Executive Officer, Aashish Mehta, shares how the company is navigating product development, adoption challenges, and regulatory compliance as it expands into global markets. Edited excerpts-
-

What are TacnIQ AI's current and future milestones – in terms of product development, launches, partnerships, and global expansion?
Over the past year, we've moved quickly, from concept to pilot to production. Backy is already live with partners like DHL, where it's helping reduce posture-related strain and injury risk by over 65 per cent. We're also working with hospitals to test applications in clinical and eldercare environments. In parallel, we've partnered with the British Standards Institution (BSI) to contribute to emerging digital safety standards.
Looking ahead, we're focused on scaling and evolving the technology. The next version of Backy will feature smarter AI agents that can not only detect unsafe posture but also automatically generate safety guidance and reduce manual reporting.
Geographically, we're expanding beyond Southeast Asia to Europe and North America, especially in logistics, aged care, and manufacturing. We're also working to integrate Backy with insurers and enterprise EHS (Environmental Health and Safety) software so that it becomes a core part of workplace wellness and safety ecosystems, not just a standalone device.
Are you planning to raise more funds this year or next? Please share details.
Denne historien er fra BioSpectrum Asia Sep 2025-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Listen
Translate
Change font size